CERE News and Press, Ceres Inc. From 12/19/22

Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline in 24-hour ambulatory systolic blood pressure at week eight of -2.7 mmHg for 10 mg QD a...

Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS total score at six weeks and was overall well-tolerated compared with p...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2022 Q3 - Results - Earnings Call Presentation

Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2022 Earnings Conference Call November 08, 2022, 08:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Anthony Coles - Chairperson and Chief Executive Officer Ray...

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. ...

Cerevel Therapeutics press release ( NASDAQ: CERE ): Q3 GAAP EPS of -$0.66 misses by $0.04 . Cash, cash equivalents and marketable securities as of September 30, 2022, were $1,030 million, inclusive of $238.3 million For further details see: Cerevel Therapeut...

Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclid...

Summary Neurocrine announced another better-than-expected quarter for Ingrezza, as enhanced sales efforts are driving reacceleration in sales. The company will be announcing Phase II results from multiple programs over the next year, and while these are high-risk programs, success...

BofA Securities has initiated Cerevel Therapeutics ( NASDAQ: CERE ) with a buy rating lauding its platform of novel receptor-selective therapeutic agents for neuropsychiatric indications. The firm has a $39 price target (~52% upside based on Thursday's close) Cerevel's...

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8...